Obtention of enantiomerically pure 5,5,5-trifluoro-l-isoleucine and 5,5,5-trifluoro-l-alloisoleucine
摘要:
The fluorinated amino acids 5,5,5-trifluoro-L-isoleucine and 5,5,5-trifluoro-L-alloisoleucine constitute a pair of diastereoisomers with attractive properties as synthons for the obtention of biologically active molecules. However, difficulties in their synthesis and chiral resolution have restricted their use to a few examples of in vivo and in vitro applications. Here we described an alternative synthetic pathway for these highly valuable fluorinated amino acids and further resolution into enantiomerically pure samples by aminoacylase-catalyzed hydrolysis of their N-acetyl derivates. Resolution is achieved by means of distinctive preference toward substrate stereochemistry exhibited by acylase I from Aspergillus melleus compared to the analogous enzyme derived from porcine kidney. Straightforward access to enantiomerically pure samples for these fluorinated amino acids will definitely expand their relevance as building blocks for the production of new drugs and innovative biomaterials. (C) 2013 Elsevier B.V. All rights reserved.
The invention provides isolated nucleic acid encoding one or more gene products that allow for degradation of caffeine and related structures, and for preparation of intermediates in that catabolic pathway. Further provided are methods of using one or more of those gene products.
CAFFEINE RESPONSIVE PROMOTERS AND REGULATORY GENES
申请人:Uinversity of Iowa Research Foundation
公开号:US20150184166A1
公开(公告)日:2015-07-02
The invention provides isolated N-demethylase genes and caffeine responsive proteins.
本发明提供了分离的N-去甲基化酶基因和咖啡因响应蛋白。
Modified factor VIII and factor IX genes and vectors for gene therapy
申请人:Asklepios Biopharmaceutical, Inc.
公开号:EP2848253A1
公开(公告)日:2015-03-18
The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
本发明涉及一种经过修饰和优化的因子 VIII 或因子 IX 核酸,可用于嵌合病毒载体。这种载体可用于治疗血友病。
Synthetic oplophorus luciferases with enhanced light output
申请人:Promega Corporation
公开号:US10233485B2
公开(公告)日:2019-03-19
A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO:1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
一种编码修饰荧光素酶多肽的多核苷酸。修饰的荧光素酶多肽与野生型Oplophorus荧光素酶至少有60%的氨基酸序列相同性,并在与SEQ ID NO:1的野生型Oplophorus荧光素酶中的氨基酸相对应的位置上包括至少一个氨基酸替换。相对于野生型Oplophorus荧光素酶,修饰的荧光素酶多肽具有增强的发光、增强的信号稳定性和增强的蛋白质稳定性中的至少一种。
Modified soluble VEGF receptor-1 genes and vectors for gene therapy
申请人:Samulski Richard J.
公开号:US10385112B2
公开(公告)日:2019-08-20
The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.